Abstract
The administration of Ocrevus, an infusion therapy for the treatment of multiple sclerosis, is time and labor intensive, leading to poor patient adherence, treatment delays due to scheduling issues, and significant staff workload. This problem worsened during the COVID-19 pandemic, which created scheduling difficulties due to space restrictions. A US Food and Drug Administration-approved rapid infusion protocol for Ocrevus decreases the infusion time by 1.5 hours per patient. The purpose of this project was to complete a literature review on rapid infusion protocols and analyze the effects of the Ocrevus rapid infusion protocol on 2 outcomes of interest: total visit time and infusion reaction rates. Data were collected using retrospective chart review and analyzed by comparing the results of each outcome to the same data points prior to the implementation of the project. Results found a statistically significant decrease in visit time, with no increase in infusion reaction rates. These findings support the implementation of this rapid Ocrevus infusion protocol in the outpatient setting with the potential to improve patient scheduling, patient satisfaction, and nursing workload, while maintaining patient safety.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference22 articles.
1. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study;Pritchard;BMC Musculoskelet Disord,2014
2. Rapid infusion rituximab changing practice for patient care;Zahrani;J Oncol Pharm Pract,2009
3. One hour Rituxan infusion is safe and improved patient care and outpatient unit management;Aurran-Schleinitz;Am Soc Hematol,2005
4. A nurse can safely deliver rituximab over 90 minutes;Corey;Oncol Nurs Forum,2007
5. The challenge of staffing in ambulatory infusion settings;Nevidjon;Clin J Oncol Nurs,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献